Dr. Vincent Falanga is Emeritus Professor of Dermatology at Boston University School of Medicine. A dedicated researcher, clinician, and educator, Dr. Vincent Falanga has had a longstanding relationship with the Boston University community. For the past 15 years, Dr. Falanga has been a Professor Biochemistry at the Boston University School of Medicine (BUSM). In addition, he served as the Assistant Dean of Clinical and Faculty Affairs, as well as the Director of the Boston University Medical Students Ambulatory Medical Clerkship at Roger Williams Medical Center (RWMC), a research and clinical affiliate of the BUSM. From 1998 to 2013, he was the Chairman and Program Director of the Department of Dermatology at RWMC. Prior to that, Dr. Falanga held several academic appointments, including an initial one at the University of Pittsburgh School Of Medicine, and then as Professor of Dermatology and Medicine at the Miller School of Medicine at the University of Miami. A graduate of Harvard Medical School, Dr. Falanga received training in Internal Medicine and Dermatology at the University of Miami and the University of Pennsylvania, respectively. He is Board certified in both Medicine and Dermatology. In 2004, he was the President of the Wound Healing Society, the premier research organization in the world dedicated to wound healing.
Vincent Falanga’s remarkable research career began in the fields of molecular and cell biology, evolving over the years to groundbreaking human-based translational research. He made seminal contributions to the expansion and growth of single cells in low oxygen tension and to the effects and transcriptional regulation of transforming growth factor-ß 1 (TGF-ß1). Dr. Falanga later focused his efforts on human recombinant growth factors and was the first to use a recombinant growth factor (EGF) in human non-healing wounds. He showed that systemic anabolic steroids can heal the painful skin ulcers due to cryofibrinogenemia and that doubling the dose of systemically administered pentoxifylline will heal venous ulcers. In 1998, he was the lead author in the use of living bioengineered skin in non-healing wounds, which led to the first ever FDA approval of bioengineered skin for accelerating wound closure. In 2007, he was the first to successfully use autologous cultured bone marrow-derived mesenchymal stem cells in human chronic wounds. In his new role as the Department of Dermatology’s Vice Chair for Research, Dr. Falanga will spearhead and coordinate many of the research projects related to tissue injury, repair processes, and regeneration. The School of Medicine and the Department of Dermatology are currently building a Good Manufacturing Practice (GMP) facility in which Dr. Falanga will oversee the research and development of novel treatments utilizing the therapeutic potential of stem cells in the care of chronic wounds caused by disorders ranging from diabetes to autoimmune disease. The GMP facility promises to enrich the translational capabilities of the Medical Center in Dermatology and other specialties. His current project with stem cells in human wounds is funded by the National Institutes of Health, which has awarded Dr. Falanga more than $45 million over the course of his career.
- Research Professor, Biochemistry, Boston University School of Medicine
- Harvard Medical School, MD
- College of the Holy Cross, BA
- Published on 7/21/2022
Falanga V, Isseroff RR, Soulika AM, Romanelli M, Margolis D, Kapp S, Granick M, Harding K. Chronic wounds. Nat Rev Dis Primers. 2022 Jul 21; 8(1):50. PMID: 35864102.
- Published on 5/19/2022
Falanga V, Grada A, Otero-Vinas M, Lin X, Yufit T, Fiore D, Carson P. Autologous Cultured Bone Marrow-Derived Mesenchymal Stem Cells in a Fibrin Spray to Treat Venous Ulcers: A Randomized Controlled Double-Blind Pilot Study. Surg Technol Int. 2022 May 19; 40:47-54. PMID: 35168289.
- Published on 6/28/2021
Otero M, Lin X, MacLauchlan S, Carson P, Falanga V. Dermal Fibroblasts from Chronic Wounds Exhibit Paradoxically Enhanced Proliferative and Migratory Activities that May be Related to the Non-Canonical Wnt Signaling Pathway. Surg Technol Int. 2021 06 28; 39:59-66. PMID: 34181242.
- Published on 11/10/2019
Obagi Z, Damiani G, Grada A, Falanga V. Principles of Wound Dressings: A Review. Surg Technol Int. 2019 11 10; 35:50-57. PMID: 31480092.
- Published on 10/1/2018
Grada A, Mervis J, Falanga V. Research Techniques Made Simple: Animal Models of Wound Healing. J Invest Dermatol. 2018 10; 138(10):2095-2105.e1. PMID: 30244718.
- Published on 10/2/2017
Ferrer-Sola M, Sureda-Vidal H, Altimiras-Roset J, Fontsere-Candell E, Gonzalez-Martinez V, Espaulella-Panicot J, Falanga V, Otero-Viñas M. Hydrosurgery as a safe and efficient debridement method in a clinical wound unit. J Wound Care. 2017 10 02; 26(10):593-599. PMID: 28976826.
- Published on 2/1/2017
Grada A, Otero-Vinas M, Prieto-Castrillo F, Obagi Z, Falanga V. Research Techniques Made Simple: Analysis of Collective Cell Migration Using the Wound Healing Assay. J Invest Dermatol. 2017 Feb; 137(2):e11-e16. PMID: 28110712.
- Published on 2/1/2017
Grada A, Falanga V. Cryofibrinogenemia-Induced Cutaneous Ulcers: A Review and Diagnostic Criteria. Am J Clin Dermatol. 2017 Feb; 18(1):97-104. PMID: 27734332.
- Published on 10/26/2016
Grada A, Falanga V. Novel Stem Cell Therapies for Applications to Wound Healing and Tissue Repair. Surg Technol Int. 2016 Oct 26; 29:29-37. PMID: 27728944.
- Published on 8/1/2016
Alani RM, Larson A, Falanga V. Paving a New Path Towards Academic Medicine-A Novel Approach to Graduate Medical Education in the United States. Acad Med. 2016 08; 91(8):1039-40. PMID: 27465087.
View 315 more publications: View full profile at BUMC